Klusa Vija, Beitnere Ulrika, Pupure Jolanta, Isajevs Sergejs, Rumaks Juris, Svirskis Simons, Dzirkale Zane, Kalvinsh Ivars
Department of Pharmacology, Faculty of Medicine, University of Latvia, Raina blv. 19, 1586 Riga, Latvia.
Medicina (Kaunas). 2013;49(7):301-9.
This review for the first time summarizes the data obtained in the neuropharmacological studies of mildronate, a drug previously known as a cardioprotective agent. In different animal models of neurotoxicity and neurodegenerative diseases, we demonstrated its neuroprotecting activity. By the use of immunohistochemical methods and Western blot analysis, as well as some selected behavioral tests, the new mechanisms of mildronate have been demonstrated: a regulatory effect on mitochondrial processes and on the expression of nerve cell proteins, which are involved in cell survival, functioning, and inflammation processes. Particular attention is paid to the capability of mildronate to stimulate learning and memory and to the expression of neuronal proteins involved in synaptic plasticity and adult neurogenesis. These properties can be useful in neurological practice to protect and treat neurological disorders, particularly those associated with neurodegeneration and a decline in cognitive functions.
